Welcome to our dedicated page for Cannara Biotech news (Ticker: LOVFF), a resource for investors and traders seeking the latest updates and insights on Cannara Biotech stock.
Cannara Biotech Inc. reports developments as a vertically integrated Canadian cannabis producer trading in the U.S. as LOVFF. The company cultivates and produces premium-grade cannabis and cannabis-derivative products for the Canadian market from two large Québec facilities, with disclosed potential annual cultivation output of 100,000 kilograms.
Recurring news includes operating and financial results, cultivation-yield and capacity updates, Valleyfield facility expansion, credit-facility amendments, asset optimization, product-category launches, provincial retail listings, and equity incentive grants. Company updates also cover exchange-listing status, including its graduation to the Toronto Stock Exchange, and governance or capital-structure actions tied to its growth plans.
Cannara Biotech (TSXV: LOVE, OTCQB: LOVFF) reported financial results for Q3 2024, showcasing impressive growth in revenues but a decline in profitability. Gross cannabis revenues rose 27.6% to $26.2 million, up from $20.6 million in Q3 2023. Total revenues, net of excise taxes, reached $19.5 million, marking a 22.6% increase. However, gross profit before fair value adjustments fell 6.1% to $5.7 million, with profitability impacted by cultivation changes. Despite industry price compression, Cannara reported its thirteenth consecutive quarter of positive Adjusted EBITDA at $2.8 million and net income of $2.0 million. Operating income stood at $3.6 million, buoyed by a $2 million gain from the sale of unused land.
Operational highlights include entering the Manitoba market, launching new genetics, and expanding in Quebec. Financial highlights show increased free cash flow to $1.2 million and earnings per share at $0.02. The company continues to invest in sales and marketing to capture more market share.
Cannara Biotech Inc. reported a significant increase in net revenue and gross profit in Q2 2024, showcasing positive financial growth. The company achieved a twelfth consecutive quarter of positive Adjusted EBITDA, indicating strong operational performance. Despite facing some challenges, including a net loss primarily due to non-cash fair value changes, Cannara remains focused on expanding its market presence and improving financial stability.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.